Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2016.
Cash and investments in marketable securities at December 31, 2016 were $389.1 million as compared to $308.9 million at December 31, 2015.
"Nektar begins 2017 in a strong position with highly promising wholly-owned immuno-oncology and immunology clinical programs and several important data readouts expected throughout this year," said Howard W. Robin, Presi
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox